











































Photoactivatable metabolic warheads enable precise and safe
ablation of target cells in vivo
Citation for published version:
Benson, S, De Moliner, F, Fernandez Vargas, A, Kuru, E, Asiimwe, NL, Lee, J-S, Hamilton, L, Sieger, D,
Ribeiro Bravo, I, Elliot, A, Feng, Y & Vendrell, M 2021, 'Photoactivatable metabolic warheads enable precise
and safe ablation of target cells in vivo', Nature Communications. https://doi.org/10.1038/s41467-021-
22578-2
Digital Object Identifier (DOI):
10.1038/s41467-021-22578-2
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were
made
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
ARTICLE
Photoactivatable metabolic warheads enable
precise and safe ablation of target cells in vivo
Sam Benson1, Fabio de Moliner1, Antonio Fernandez1, Erkin Kuru2,3, Nicholas L. Asiimwe 4, Jun-Seok Lee 5,
Lloyd Hamilton6, Dirk Sieger 6, Isabel R. Bravo1, Abigail M. Elliot1, Yi Feng 1✉ & Marc Vendrell 1✉
Photoactivatable molecules enable ablation of malignant cells under the control of light, yet
current agents can be ineffective at early stages of disease when target cells are similar to
healthy surrounding tissues. In this work, we describe a chemical platform based on amino-
substituted benzoselenadiazoles to build photoactivatable probes that mimic native meta-
bolites as indicators of disease onset and progression. Through a series of synthetic deri-
vatives, we have identified the key chemical groups in the benzoselenadiazole scaffold
responsible for its photodynamic activity, and subsequently designed photosensitive meta-
bolic warheads to target cells associated with various diseases, including bacterial infections
and cancer. We demonstrate that versatile benzoselenadiazole metabolites can selectively
kill pathogenic cells - but not healthy cells - with high precision after exposure to non-toxic
visible light, reducing any potential side effects in vivo. This chemical platform provides
powerful tools to exploit cellular metabolic signatures for safer therapeutic and surgical
approaches.
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S ince the early 1990s, photodynamic therapy (PDT) has beenclinically used as a therapeutic approach to ablate patho-genic and malignant cells in various diseases, from bacterial
infections to cancer1. PDT combines light, oxygen, and photo-
sensitizers to produce toxic reactive oxygen species locally, and
cause cell death. A broad range of chemical architectures have
been reported as effective PDT agents, including organic and
inorganic molecules2–6, superoxide radical generators7, 8, core-
shell metal nanoparticles9, 10, metal-organic frameworks11–13, and
mesoporous organosilica nanoparticles14. Recently, the groups of
Gasser, Chao, and Sadler described the use of highly oxidative
iridium photocatalysts to induce intracellular redox imbalance
and kill cancer cells even in the presence of low concentrations of
oxygen15. In addition to exhibiting high phototoxic potential, a
critical requirement for PDT agents is to exhibit toxicity only in
target cells so that therapeutic benefit can be achieved with tol-
erable light doses and minimal side effects in healthy tissues.
Different strategies have been described to fine-tune the struc-
tures of photosensitizers and enhance their cell selectivity. Acti-
vatable agents exploit some of the biochemical features of tumors
(e.g., low pH, glutathione, proteases) to release photosensitizers in
cancerous tissues, showing promise in reducing bystander
toxicity10, 16–20. Alternatively, photosensitizers can be conjugated
to antibodies, which favor accumulation in tissues that express
specific cell-surface markers21, 22. Whereas these approaches can
be effective in the presence of abundant biomarkers, they show
limitations at early stages of disease when the biochemical and
proteomic signatures of target cells are not dissimilar to those of
surrounding healthy tissues (e.g., microtumors). Chemical designs
to directly deliver photosensitizers to individual pathogenic and
malignant cells under in vivo physiological conditions would
significantly extend the clinical applications of PDT.
Cellular metabolism is a reliable indicator of disease onset and
frequently used in the clinic (e.g., metabolomics can assist in the
detection and therapy stratification of infection23 and cancer
patients)24, 25. The metabolic patterns of cells belonging to dif-
ferent taxa (e.g., prokaryotic vs eukaryotic cells) or with altered
energetic demands (e.g., cancer vs healthy cells, due to the
Warburg effect)26 are unique; however, light-controlled ablation
of cells on the basis of differential or altered metabolism has been
negated by the lack of photosensitive chemical structures that
retain the properties of native metabolites.
Most photosensitizers are derived from bulky fluorescent
scaffolds27–29, which impair their active uptake as photosensitive
metabolites. Smaller fluorophores, such as pyrroloindolizines,
nitrobenzodiazoles, and naphthylamines30–32 are more appropriate
to retain metabolite function. In this work, we have designed a
platform based on amino-substituted benzoselenadiazoles as the
smallest photosensitizers reported to date and used them to build
photodynamic agents that recapitulate the uptake of native meta-
bolites, unlike some commercial photosensitizers. Benzoselenadia-
zole probes can selectively kill cells exhibiting altered metabolism
with high spatial resolution and only after exposure to nontoxic
light. Importantly, we demonstrate that benzoselenadiazoles are
compatible with different metabolite structures (e.g., amino acids,
saccharides) and can be used to ablate a variety of disease-causing
cells, from bacterial pathogens in vitro to glioblastoma microtumors
in vivo. This chemical platform demonstrates how small photo-
sensitizers can harness early metabolic signatures to safely eliminate
harmful cells in vivo without damaging healthy tissues.
Results
Amino-substituted nitrobenzoselenadiazoles are small photo-
sensitizers. In order to generate photosensitizers that would not
impair the biomolecular properties of native metabolites, we
focused on the nitrobenzodiazole core as an example of a small
and uncharged chromophoric scaffold33. With the exception of
nitrobenzoxadiazoles (e.g., NBD-Cl, Fig. 1a), which are com-
mercially available, we employed the diamine 1 to prepare
nitrobenzodiazoles including different bridging atoms, namely
sulfur, selenium, or carbon (Fig. 1a, full synthetic and char-
acterization details in Supplementary Information). Thio- and
selenoderivatives (3, 4) were prepared by condensation of the
diamine 1 with N-sulfinylaniline or SeO2 respectively, followed by
nitration of the position 7 under acidic conditions. The synthetic
route for the carbon derivative 5 was modified due to the lability
of aminoacetals under strong acidic conditions, which would
deter the nitration step. Therefore, we treated nitrobenzoselena-
diazole 4F with HI and HCl to remove the selenium atom and
performed a Cu-catalyzed condensation with acetone to obtain
the corresponding carbon-bridged nitrobenzodiazoles (5). All
nitrobenzodiazoles were treated with diethylamine and isolated as
the corresponding aminoderivatives (2a–5a, Fig. 1a), which
absorb in the visible spectral range. Despite some of these com-
pounds having a relatively high number of N atoms, all of them
fulfill the rule of 3 (i.e., the number of C and O atoms divided by
the number of N atoms is equal or larger than 3) and therefore
are deemed safe to handle and store34.
Compounds 2a–5a showed absorbance maxima wavelengths
between 480 and 565 nm (Supplementary Table 1); however, only
the selenium derivative (4a) displayed high cellular toxicity after
exposure to the light dose generally used in clinical PDT (i.e., 37J
cm−2, Fig. 1b)35. Remarkably, the nitrobenzoselenadiazole 4a
displayed minimal cell death in the dark (<10%) and almost
complete cell ablation (>90%) after irradiation, whereas none of
the other compounds (2a, 3a, and 5a) showed significant
differences between dark and light-induced cytotoxicity (Fig. 1b).
These observations were supported by DFT (Density Functional
Theory) calculations (Supplementary Fig. 1). These indicated
that, whilst all compounds had sufficient energy to excite 3O2 to
1O2 via their S0-T2 transition, the energy levels of the
benzoselenadiazole 4a showed the smallest energy gap for
intersystem crossing between S1 and T2 excited states, which
favors the occupation of the T2 state and the probability of singlet
oxygen production under light irradiation. Furthermore, the
degree of spin orbital coupling induced by selenium is 5-fold
higher than for other heteroatoms36, which significantly increases
the probability of accomplishing this formally forbidden electro-
nic transition. Collectively, these results highlight the heavy
selenium atom as a critical feature to endow the nitrobenzodia-
zole core with unique photosensitive capabilities.
Previous reports have described the importance of the
substituents in the position 4 of nitrobenzodiazoles to fine-tune
their optical properties37. Therefore, we synthesized a subset of
nitrobenzoselenadiazoles where the position 4 was functionalized
with different nucleophiles and aromatic groups to assess whether
those would influence phototoxicity. Benzoselenadiazoles including
amines, phenols, thiophenols, and aryl groups (compounds 6–9,
Fig. 1c) were synthesized by nucleophilic substitution under basic
conditions or by conventional Pd-catalyzed Suzuki couplings (full
synthetic and characterization details in Supplementary Informa-
tion). Spectral characterization confirmed that amino-substituted
analogs presented an effective push-pull dipole as indicated by their
longer excitation wavelengths (Fig. 1d). Amino-substituted nitro-
benzoselenadiazoles showed the highest phototoxicity in cells
compared to all other substituents and to the control compound
4F (Fig. 1d). We also examined whether the incorporation of
additional heavier atoms in nitrobenzoselenadiazoles—such as
iodine, already reported for the successful conversion of other
fluorescent structures into photosensitizers38—would further
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improve their phototoxic potential. We employed the commercially
available mono-iodinated diamine 10 to synthesize 9-diethylamino-
6-iodo-7-nitrobenzoselenadiazole (11a) as described above (Fig. 1c;
full synthetic details in Supplementary Information) and compared
its behavior to the parent non-iodinated compound (4a). Both
compounds 4a and 11a presented similar excitation wavelengths
around 500 nm, with the latter exhibiting dark cytotoxicity and the
non-iodinated derivative showing higher ratios of phototoxicity,
making it more suitable for the preparation of photosensitive
metabolites. Finally, we examined the mechanism by which amino-
substituted nitrobenzoselenadiazoles induce oxidative death39 and
confirmed that, upon light irradiation, they predominantly produce
singlet oxygen over radical anions (approximately in a 75:25 ratio,
Supplementary Fig. 2). Amino-substituted nitrobenzoselenadiazoles
are therefore one of the smallest photosensitizer structures reported
to date.
Benzoselenadiazole-conjugated amino acids retain stereo-
specific recognition of bacterial cells. In view of the suitable
properties of benzoselenadiazoles as small and uncharged photo-
sensitizers, we examined their impact on the molecular recognition
properties of metabolites, such as amino acids. VanNieuwenhze,
Brun and co-workers have demonstrated that derivatives of D-amino
acids (e.g., D-alanine) but not L-amino acids can be recognized by the
metabolic cell wall machinery of bacterial cells and incorporated into
Fig. 1 Synthetic routes for the preparation of small photosensitizers. a Condensation of 1 with PhNSO or SeO2 followed by nitration led to compounds 3
and 4F, respectively. Reduction of 4F followed by Cu-catalyzed addition of acetone rendered compound 5. Nucleophilic substitutions of 2–5 with
diethylamine yielded 2a–5a. b Human U87 cells were incubated with 2a–5a (100 μM) in Krebs–Ringer buffer and illuminated (red bars) or not (gray bars)
with a ThorLabs M530L3 LED (10mW, 37 J cm−2, red). Cell viability was assessed 16 h post illumination using a TACSR MTT cell proliferation assay with
values normalized to the viability of untreated cells. Data presented as mean values ± SEM (n= 3 independent experiments). c Nucleophilic substitution of
4F with piperidine, 4-methoxyphenol, and 4-mehtoxythiophenol led to compounds 6, 7, and 8, respectively. Suzuki coupling of 4Cl with methoxybenzene-
4-boronic acid rendered compound 9. Condensation of compound 10 with SeO2 followed by nitration and nucleophilic substitution resulted in compound
11a. d Maximum excitation wavelengths and phototoxicity of compounds 2a–11a and 4F in human cells as determined in (b). Values indicate the decrease
in viability between irradiated and non-irradiated cells after incubation with compounds 2a–11a (100 μM). P values were obtained from two-tailed unpaired
t tests. Source data are available.
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their peptidoglycan cell walls (Fig. 2a)40, 41. Therefore, we prepared
benzoselenadiazole derivatives of D- and L-alanine to examine
whether the stereospecific incorporation of the D-enantiomer would
be retained after conjugation to the photosensitizer. Two amino
acids (12, the L-alanine surrogate and 13, the D-alanine surrogate,
Fig. 2b) were synthesized by nucleophilic substitution of the
fluorinated benzoselenadiazole 4F with the two enantiomers of
2,3-diaminopropionic acid (Dapa) (Fig. 2b, full synthetic details in
Supplementary Information). Both amino acids exhibited similar
optical properties and singlet oxygen quantum yields, indicating
comparable phototoxicity potential (Supplementary Table 1).
During the synthesis of peptidoglycans in the bacterial cell wall,
the nascent peptide chains are specifically capped with D-alanines,
which can be selectively exchanged by exogenously provided
unnatural D-amino acids (Fig. 2a)42. To monitor the effect of the
amino acids in bacterial cells, we grew Gram-negative Escherichia
coli in the presence of compounds 12 or 13 and imaged the cells
shortly after by fluorescence microscopy. We observed that E. coli
Fig. 2 Benzoselenadiazole D-amino acids can be incorporated into bacteria for light-controlled antimicrobial ablation. a D-alanine is incorporated into
the positions 4 or 5 of peptidoglycan structures. Incorporation followed by illumination results in the production of singlet oxygen and concomitant cell
death (Gln: N-acetylglucosamine, Mur: N-acetylmuramic acid). b Synthesis of the amino acids 12 and 13 by conjugation of 4F with enantiomers of 2,3-
diaminoproprionic acid. c Brightfield and fluorescence microscopy images of E. coli after incubation with compounds 12 and 13 (250 μM). Scale bar: 10 μm.
The viability of bacterial cells was measured by optical density (600 nm) after incubation at 30 °C with or without compounds 12 or 13 and illumination
using white LED. Data normalized to the viability of light-only treated cells and presented as mean values ± SEM (n= 2 independent experiments). d Time-
lapse monitoring of E. coli that had been pretreated with NADA or compound 13 (both 100 μM). Representative brightfield and fluorescence microscope
images (from three independent experiments) with excitation at 470 nm (196mW) and 508 nm (62mW) were taken every minute for 30min. Green and
red arrows indicate NADA- and 13-labeled bacteria, respectively; yellow arrowheads indicate exploding 13-labeled bacterial cells after treatment. Scale bar:
2 μm. Source data are available.
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cells incubated with the D-amino acid 13 -but not the L-amino
acid 12- showed uniform labeling of the bacterial septa, indicating
that the benzoselenadiazole scaffold retained the selectivity of D-
alanine (Fig. 2c). We confirmed by mass spectrometry that the D-
amino acid 13 was covalently incorporated into the peptidoglycan
cell wall (Supplementary Fig. 3) and that the incorporation was
independent of the bacterial strain, as shown in experiments with
Gram-positive bacteria, such as the model species Bacillus subtillis
and the pathogen Staphylococcus aureus (Supplementary Fig. 3).
We also examined whether compound 13 could kill E. coli after
light irradiation. E. coli bacterial colonies were treated with
compounds 12 (as a negative control) or 13 and kept in the dark
or irradiated with light, followed by proliferation measurements
under both conditions. As shown in Fig. 2c, high levels of cell
death were observed in 13-treated and light-irradiated E. coli cells
(<10% cell viability) whereas minimal toxicity was detected in
non-irradiated cells or cells that had been incubated with the
control compound 12. Finally, we performed time-lapse imaging
of E. coli cocultures that had been separately pre-labeled with
compound 13 or NADA (Fig. 2b). NADA is a reported
nitrobenzoxadiazole D-alanine analog lacking the selenium atom
and able to fluorescently stain bacterial cell walls43. The amino
acids NADA and 13 fluorescently labeled E. coli cells (λem
(NADA): 530 nm, λem (13): 590 nm), and their growth was
monitored for 30 min while irradiating the cells at regular
intervals. Remarkably, most NADA-labeled cells showed clear
signs of continued growth and proliferation over time, whereas
cells that had been pretreated with compound 13 appeared as
lysed or showed arrested cell growth (Fig. 2d). These results
support that the local production of singlet oxygen after the
irradiation of peptidoglycan-incorporated benzoselenadiazoles
can selectively target and kill bacterial cells with high spatial
resolution and without affecting neighboring cells in the close
vicinity. Given that compound 13 can be effectively incorporated
into Gram-negative and Gram-positive bacteria and cause cell
death upon light irradiation, these molecules could open avenues
to develop antibiotic regimes overcoming complications asso-
ciated to antimicrobial resistance in pathogenic bacteria.
A 2-deoxyglucose benzoselenadiazole photosensitizer enables
light-controlled ablation of human glioblastoma cells in vitro
and in 3D spheroids. Glioblastomas are the most common and
one of the most aggressive types of brain cancer, where surgical
treatments require highly precise and safe strategies to remove
malignant cells without affecting healthy tissues. Brain tumor
cells are very glycolytic and show increased levels of glucose
consumption when compared to healthy tissue44, hence we
decided to assess whether glucose-derivatized benzoselenadiazoles
could kill human glioblastoma cells after exposure to
nontoxic light.
Two D-glucose analogs (compounds 14 and 15, Fig. 3a) were
synthesized by condensation of the benzoselenadiazole scaffold 4F
with two 2-D-deoxyglucosamine analogs. Both compounds were
isolated as the mixture of α- and β- anomers of D-glucose
(characterization data in Supplementary Information). Compound
15 showed better water solubility and photoreactivity than
compound 14, thus we assessed whether it could be actively taken
up by GLUT1/3 transporters in glioblastoma cells, the most
abundant glucose transporters in human U87 cells45. As controls,
we also prepared D-glucosamine derivatives of previously reported
photosensitizers, such as Nile Blue reported by Fowley and co-
workers46 and tetraphenylethylene (TPE) reported by the Bin Liu
et al. for metabolic PDT47 (compounds 16 and 17, respectively,
Fig. 3b). First, we compared the uptake for all D-glucose derivatives
in U87 cells. As shown in Fig. 3c, compound 15 — but not Nile
Blue (16) or TPE (17) derivatives—exhibited reduced uptake in cells
that had been pre-incubated with the GLUT inhibitor cytochalasin
B, suggesting that compound 15—unlike other photosensitizers—
can enter glioblastoma cancer cells through active uptake via GLUT
transporters. We also analyzed whether the phototoxicity of
compound 15 in U87 cells was dependent on GLUT-mediated
transport and observed that its activity was significantly blocked
with cytochalasin B (Fig. 3c). Furthermore, compound 15 showed
the highest singlet oxygen generation quantum yield among all
aminobenzoselenadiazoles (Fig. 3d), with values around 25%—
comparable to TPE—and produced effective amounts of singlet
oxygen by single-photon (520 nm) in vitro and in cells as well as by
two-photon (970 nm) excitation (Supplementary Fig. 4). Given the
technical complexity of two-photon in vivo experiments and the
limited availability of multi-photon illumination in clinical settings,
we decided to perform our biological characterization using single-
photon excitation.
We cultured human U87 glioblastoma cells and incubated them
with compound 15 to directly image the viability of the cells in the
dark as well as after light irradiation. Because photosensitizers
producing singlet oxygen induce oxidative cell death via
apoptosis48, we used the apoptotic marker Annexin V as an
indicator of the toxicity caused by compound 15. Confocal
fluorescence microscopy confirmed that U87 glioblastoma cells
that had taken up compound 15 (as shown by intracellular red
staining, Fig. 4a) were apoptotic (blue cell membrane staining by
Annexin V-Pacific Blue, Fig. 4a) only after light irradiation but not
in the dark. On the other hand, single treatments (i.e., compound
15 only or light irradiation only) did not cause cell death as
confirmed by fluorescence microscopy and quantitative flow
cytometry (Fig. 4b). We also confirmed that compound 15 would
compete with unlabeled D-glucose, which drastically reduced the
uptake and phototoxicity of compound 15 (Fig. 4a). Furthermore,
as a control we used 2-NBDG, the non-photosensitive nitroben-
zoxadiazole glucose analog (Fig. 3a) and confirmed that the
selenium atom in the benzoselenadiazole core is essential to cause
light-induced oxidative death (Fig. 4b). Finally, we examined the
toxicity of compound 15 in 3D cultures from U87-nlsCrimson
glioblastoma cells, which express the fluorescent protein E2Crim-
son in their nuclei as a cell viability marker (λexc/em: 610/645 nm).
U87-nlsCrimson cells were cultured in ultra-low adherence plates
at 37 °C, forming spheroids of around 250 µm in diameter after
3 days. We compared the size of the spheroids in the absence and
presence of compound 15 as well as before and after irradiation
(Fig. 4c, d). Compound 15-treated and irradiated spheroids
showed a significant decrease in the size of the cell viable core
when compared to any of the other incubation conditions,
indicating that compound 15 can effectively kill cells in multiple
layers of 3D glioblastoma spheroids.
Compound 15 shows high potency and selectivity for glio-
blastoma cells in cocultures of human brain cells. In view of the
potential of compound 15 to act as a PDT agent for glioblastoma,
we examined its ability to selectively kill glioblastoma cells when
they were cultured in the presence of non-cancerous brain cells.
We cocultured the glioblastoma cell line U87-nlsCrimson with
human HCN-2 cells as representative non-cancerous neuronal
precursor cells49. HCN-2 cells were pre-stained with CellMask
Green and cocultured with U87-nlsCrimson cells (Fig. 5a). Under
normal coculture conditions, both HCN-2 and U87 cells were
viable, as indicated by fluorescence emission of their respective
markers (i.e., CellMask Green for HCN-2, E2Crimson for U87,
Fig. 5b). Cocultures were then incubated with compound 15,
irradiated with visible light at 37 J cm−2, and monitored by
fluorescence confocal microscopy. Notably, the combination
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treatment of compound 15 and light-induced cell death in most
U87 cells—as shown by the lack of fluorescence in the E2Crimson
channel—but not in HCN-2 cells, which are less glycolytic and
metabolically-active (Fig. 5b). Plot profile analysis confirmed that
HCN-2 cells remained intact after the treatment whereas U87
cells were devoid of E2Crimson fluorescence (Fig. 5c). Further-
more, we confirmed that cocultures which had not been treated
with compound 15 or not exposed to light showed no signs of
death in any cell type (Supplementary Fig. 6). Finally, we analyzed
the solubility and phototoxicity profiles of compound 15 and 5-
aminolevulinic acid (5-ALA, Fig. 5d), the current gold standard in
image-guided surgery for brain tumor resection. 5-ALA stimu-
lates the production of protoporphyrin IX in tumor cells and is
currently evaluated in clinical trials for postoperative and inter-
stitial PDT50. Both compound 15 and 5-ALA showed full water
solubility in the high micromolar range, and we did not detect the
formation of any aggregates with diameter size >10 nm. We also
compared the in vitro toxicity of different concentrations of
compound 15 and 5-ALA in U87 glioblastoma cells and observed
that compound 15 was able to induce significant levels of cell
death at similar doses as 5-ALA and with complete lack of
toxicity in HCN-2 cells (Fig. 5e). Taken together, these results
highlight the biocompatibility and potential utility of compound
15 for light-controlled ablation of cancer cells with comparable
phototoxicity to PDT agents under clinical evaluation.
Compound 15 enables safe removal of microtumors in vivo.
Encouraged by the selective photoreactivity of compound 15 in
metabolically-active cancer cells, we evaluated whether it could be
used to eliminate small tumors derived from human glioblastoma
cells in vivo. We used a zebrafish model where low numbers of
glioblastoma cells (around 50 ± 10 cells per organism) were injected
into the yolk sac of 2-day-old embryo and allowed to form
microtumors51–53. In order to quantify the viability of tumor cells
by fluorescence confocal microscopy, we used the above described
U87-nlsCrimson cells since they express a live-cell fluorescent
reporter that can be detected in the optically-transparent zebrafish.
As expected, the injection of U87-nlsCrimson cells into zebrafish
Fig. 3 D-Glucose derivatives of benzoselenadiazole— but not of other photosensitizers—are recognized by GLUT transporters. a Chemical synthesis of
the D-glucose aminobenzodiazole compounds 14 and 15, and the non-photosensitive control compound 2-NBDG. b Structures of D-glucose derivatives of
the photosensitizers Nile Blue (compound 16) and tetraphenylethylene (TPE, compound 17). Full synthetic and characterization details described in the
Supplementary Information. c Flow cytometric quantification (gating: Supplementary Fig. 5) of uptake of D-glucose derivatives in human U87 cells
(200,000 cells/well) after incubation for 1 h with compounds 15–17 (50–100 μM) in Krebs–Ringer buffer in the presence or not of the GLUT inhibitor
cytochalasin B (20 μM) (λexc/em 488/610 nm (15), 635/670 nm (16), 355/450 nm (17)). Phototoxicity in U87 cells after incubation with compound 15
(100 μM) in the presence or absence of cytochalasin B (20 μM). Cells were illuminated (10mW, 37 J cm−2) and viability was assessed 16 h post
illumination using a TACSR MTT cell proliferation assay with values normalized to those in cells without cytochalasin B. Data presented as mean values ±
SEM (n= 3 independent experiments). d Excitation wavelengths used for single-photon illumination (*corresponds to two-photon illumination) and singlet
oxygen generation quantum yields determined using DPBF in EtOH (Note: DPBF was found insoluble in water) using Rose Bengal as a reference (68%)61.
†Singlet oxygen generation quantum yield reported for TPE62. ¥Reported values for protoporphyrin IX, the main photosensitizer produced upon metabolism
of 5-aminolevulinic acid (5-ALA)63. P values were obtained from two-tailed unpaired t tests. Source data are available.
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embryo at 48 hpf (hours post-fertilization) led to the formation of
fluorescent tumor mass of several microns in diameter (Fig. 6a).
Tumor-bearing zebrafish were then treated with compound 15
(microinjection of 6 pg into the yolk sac) and illuminated with
visible light at a dose of 37 J cm−2. Confocal microscopy images
were taken from each group, and we quantified the number of
remaining fluorescent U87 cells in each larva (Fig. 6a, b). The
sequential treatment of compound 15 followed by light irradiation
led to a dramatic reduction of the size of the microtumors, with
some zebrafish being entirely free of glioblastoma cells after the
treatment (Fig. 6b). The injection of compound 15 or the light
irradiation of zebrafish on their own did not cause any significant
reduction in the total number of cancer cells (Fig. 6b). Finally, we
examined whether the in vivo treatment with compound 15 caused
side effects in zebrafish. First, we compared the morphology of
treated and untreated zebrafish, with no evident abnormalities
between the two groups (Supplementary Fig. 7). Next, we examined
their behavior and vital signs after the PDT treatment. Larvae from
control and treated groups showed similar swimming behavior, as
shown by the tracks of individual larva (n ≥ 10 per group, Fig. 6c)
with no significant differences in distance covered or velocity
(Fig. 6d and Supplementary Movies 1, 2). Heartbeat monitoring in
both groups also revealed that treatment with compound 15 and
light was safe and did not cause any evident deleterious side effects
(Supplementary Movies 3 and 4). In summary, our data indicate
that photosensitive metabolites represent a viable chemical strategy
to harness the aberrant early metabolic features of aggressive cancer
cells and to open avenues for minimally-invasive therapeutic stra-
tegies to safely eliminate microtumors.
In summary, this study demonstrates the utility of amino-
substituted benzoselenadiazoles as small photosensitizers to kill
metabolically-active cells in vitro and in vivo under full chemical
and light control. Unlike in other current photosensitizers, the
reduced size of benzoselenadiazoles retains key recognition
properties of native metabolites and enables cell-selective uptake
via various routes (e.g., peptidoglycan incorporation in bacteria,
glucose transport in glioblastoma cells). This chemical approach
opens therapeutic avenues for the selective ablation of cells that
do not present discriminatory cell-surface markers, such as
malignant cancer cells at early stages of disease, or that may
become resistant to existing treatments, such as pathogenic
bacteria. We also show that the dosing regime and light exposure
Fig. 4 Compound 15 kills metabolically-active human glioblastoma cells in vitro and in 3D structures. a Representative brightfield and fluorescence
images (from three independent experiments) of U87 human glioblastoma cells (20,000 cells/well) treated with compound 15 (red, λem 590 nm) or 2-
NBDG (green, λem 530 nm) (both 100 μM) with or without D-glucose (5 mM) and illuminated or not with ThorLabs M530L3 LED (10mW, 37 J cm−2).
Annexin V-Pacific blue (4 μg mL−1) was used as an apoptosis marker (blue, λem 450 nm). Scale bar: 10 μm. b Flow cytometric quantification (gating:
Supplementary Fig. 5) of apoptotic U87 cells after different treatments. Data presented as mean values ± SD (n= 4 independent experiments). c Size
decrease of U87-nlsCrimson 3D spheroids after variable treatments with compound 15 (100 μM) and visible light (10mW, 37 J cm−2). Data presented as
mean values ± SEM and normalized to the viability of untreated spheroids (n= 3 independent experiments with three technical replicates).
d Representative merged brightfield and fluorescence microscope images (from three independent experiments) of U87-nlsCrimson spheroids where live
cells expressed E2Crimson fluorescent protein (λem 645 nm, magenta). Spheroids treated with compound 15 plus light showed circumference of dead cells
of ~50 μm in diameter (blue bar). Scale bar: 100 μm. P values were obtained from two-tailed unpaired t tests. Source data are available.
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required for photosensitive metabolites meet high safety stan-
dards and are compatible with current procedures used in clinical
PDT. The possibility to ablate cells with high precision and purely
because of differential or altered metabolism will enable
mechanistic studies to identify unknown subsets of disease-
causing cells and to develop safer therapeutic approaches with
enhanced spatiotemporal resolution.
Discussion
The possibility to directly harness aberrant metabolism represents a
strategy to improve the selectivity of PDT agents54. Photosensitizers
that can enter target cells via endogenous metabolic transporters,
especially those that are expressed differentially between target cells
and their surrounding tissue, would increase selective cell ablation
and minimize potential side effects. However, among the many
chemical structures reported to date, very few photosensitizers can
utilize endogenous metabolic transporters. Herein we describe
benzoselenadiazoles as a generic photosensitizer scaffold to produce
phototoxic metabolites. The synthesis of aminobenzoselenadiazoles
from small metabolites is straightforward, with high-yielding and
scalable reactions (Fig. 1). Given that many metabolites contain
reactive amino groups (e.g., amino acids, aminoglycans, peptides),
this chemical strategy is translatable to a broad range of biological
transporters and cell types.
The lack of charged chemical groups and the small size of ben-
zoselenadiazoles are essential to retain recognition and uptake
through cell-surface transporters. Aminobenzoselenadiazoles mimic
the stereospecificity of chiral amino acids (as shown in L-Ala vs D-
Ala derivatives, Fig. 2) and replicate the uptake of natural biomo-
lecules, as demonstrated with the glucose analog 15 in GLUT
transporters (Fig. 3). Of note, GLUT-mediated transport was not
observed for other glucose-based photosensitizers, such as Nile Blue
or TPE. We have demonstrated that the active uptake of amino-
benzoselenadiazoles is essential to 1) minimize off-target toxicity in
healthy cells, as shown in human cocultures and in vivo (Figs. 5 and
6), and 2) accumulate concentrations of photosensitizer inside
target cells that can generate cytotoxic levels of singlet oxygen under
clinical PDT exposure (Figs. 4, 5, and 6). Furthermore, given that
aminobenzoselenadiazoles can be excited by single and two-photon
Fig. 5 Compound 15 selectively ablates human glioblastoma cancer cells under clinical PDT conditions and in the presence of non-cancerous human
brain cells. a Procedure for coculturing human non-cancerous brain HCN-2 cells (stained with CellMask Green) and human glioblastoma U87-nlsCrimson
cells. Cocultures (15,000 HCN-2 cells and 10,000 U87 cells per well) were incubated with compound 15 (100 μM) and illuminated with ThorLabs M530L3
LED (37 J cm−2). The fluorescence emission from E2Crimson is reduced in U87-nlsCrimson glioblastoma cells upon cell death. (b, c) Representative
brightfield and fluorescent confocal microscopy images (from three independent experiments) of cocultured HCN-2 (green, λem: 520 nm) and U87-
nlsCrimson (magenta, λem: 645 nm) before (b) and after treatment (c). Yellow arrowheads in (c) highlight dead U87h cells devoid of Crimson
fluorescence. Scale bars: 10 μm. d Phototoxicity analysis under different concentrations of compound 15 and 5-ALA in U87 glioblastoma cells (20,000
cells/well) using the same irradiation settings (10mW, 37 J cm−2). Data presented as mean values ± SEM (n= 3 independent experiments). e HCN-2 cell
viability (10,000 cells/well) after incubation with concentrations under the phototoxicity threshold [i.e., compound 15 (100 μM, red) and 5-ALA (200 μM,
blue)] and light exposure (37 J cm−2). Data presented as mean values ± SEM (n= 4 independent experiments). Source data are available.
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sources (Fig. 3 and Supplementary Fig. 4), near-infrared multi-
photon endoscopes—increasingly used for in vivo applications55, 56
—could be considered as excitation sources. Recent in human
studies combining local administration of benzodiazoles with
endoscope-based imaging suggest that this approach might be
translatable to the clinic57.
Importantly, aminobenzoselenadiazoles show PDT efficacy at a
power of 37 J cm−2, which is compatible with clinical use58.
Under these conditions, we have demonstrated that benzosele-
nadiazole D-amino acids can selectively kill bacterial cells upon
irradiation. In mammalian cells, we observed similar cytotoxicity
between compound 15 and 5-ALA, the only FDA-approved
photosensitizer able to enter cancer cells through endogenous
transporters (i.e., PepT1 and PAT1 transporters)59. Unlike 5-
ALA, compound 15 enters cancer cells within minutes and does
not need to be metabolized to be phototoxic (5-ALA is converted
to PPIX after several hours). This feature allows local adminis-
tration of the photosensitizer to minimize systemic side effects,
something that cannot be done with 5-ALA. In summary, this
chemical platform offers a safe and rapid therapeutic avenue for
the metabolic ablation of pathogenic cells, such as early-stage
cancers and drug-resistant bacteria, which prove difficult to target
with existing PDT approaches.
Methods
Density Functional Theory (DFT) calculations. B3LYP, PBE0, M06-2X, and
wB97XD functionals along with 6–31 G* and def2tzvp basis sets were tested for the
closest match between the experimental absorption maxima in ethanol and the
energy calculated for the S0→ S1 transitions of compounds 2a–5a. TD-B3LYP/
def2tzvp achieved the closest match and was used for all subsequent computations.
Bacterial cell growth. E. coli, B. subtilis, and S. aureus cells were grown to
exponential phase in LB medium at 37 oC. Cells were incubated with compounds
12, 13, or NADA at the indicated concentrations. Sacculi from labeled cells were
isolated by adding cell suspensions to boiling sodium dodecyl sulfate (SDS, 5% w/v)
and incubation for 30 min41. The SDS-insoluble material was collected by ultra-
centrifugation at 39,000xg for 10 min at 30 oC, resuspended in water and boiled
again in SDS (4% w/v) with stirring for 30 min. Samples were then washed, pel-
leted, and resuspended in the minimal amount of water. Growth curves were
measured via absorbance at 600 nm over 18 h post-incubation with probes and/or
illumination. Time-lapse microscopy experiments were performed with pre-labeled
E. coli cells spotted on LB-agarose pads with images acquired every 1 min using a
Nikon Ti2 Eclipse inverted microscope equipped with a Lumencor SPECTRA light
engine and consecutively irradiating cells under optimized conditions for NADA
(λexc/em: 470/530 nm, 196 mW) and compound 13 (λexc/em: 508/590 nm, 62 mW).
Cell culture. U87 cells (ATCC), U87-nlsCrimson cells (provided by Dr Dirk Sieger
(University of Edinburgh)), and HCN-2 cells (ATCC) were grown in DMEM med-
ium supplemented with 10–20% FBS, antibiotics (100UmL−1 penicillin, 100mgmL−1
streptomycin), and 2mM L-glutamine at 37 °C in a humidified atmosphere with 5%
CO2. Cells were passaged in T-75 cell culture flasks using trypsin-EDTA.
Photoviability experiments. U87 cells were incubated in Krebs–Ringer bicarbo-
nate buffer (KRB) for 2 h, incubated with or without compounds (2a–17) at the
indicated concentrations and illuminated or not with either a ThorLabs M530L3/
M625L4 LED or a white light source (10 mW, 37 J cm−2). Medium was replaced
with fresh DMEM, and cell viability was measured after 24 h using an MTT Cell
Fig. 6 In vivo treatment of zebrafish xenografts with compound 15 followed by light irradiation leads to safe elimination of microtumors with no
evident side effects. a Representative brightfield microscopy images (from five independent experiments) of zebrafish larvae grafted with U87-nlsCrimson
cells before treatment (top) and after the injection of compound 15 (6 pg per embryo) and light irradiation (37 J cm−2, bottom). Insets show fluorescence
microscopy images (λexc/em: 561/645 nm) of microtumors formed by U87-nlsCrimson cells, which are fully eliminated after treatment. Scale bars: 50 µm
(brightfield), 20 µm (fluorescence). b Quantification of fluorescent U87-nlsCrimson cells remaining in zebrafish larvae under different treatments. Data
presented as means ± SEM (n= 5 independent experiments). c Microscope images of superimposed pseudo-colored swimming tracks of control untreated
zebrafish larvae and double-treated (compound 15 plus light) larvae (n= 5 per group, representative videos for each group shown as Supplementary
Movies 1 and 2). d Quantification of distance and velocity of control untreated zebrafish larvae (C) and double-treated zebrafish larvae (i.e., compound 15
plus light, T) larvae. Data presented as mean values ± SEM (n= 5 independent experiments). P values were obtained from one-way ANOVA with multiple
comparisons in (b) and two-tailed unpaired t tests in (d). Source data are available.
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Proliferation assay following the manufacturer’s instructions. Values were nor-
malized to the viability of untreated cells and analyzed by GraphPad Prism.
Determination of singlet oxygen quantum yields. Solutions of DPBF (300 µM)
and compounds 2a–16 (50 µM, unless indicated otherwise) in EtOH were illu-
minated with visible light (0.3 mW) for 0.5–4 min, followed by absorbance mea-
surements at 410 nm using a Synergy spectrophotometer. Rates of singlet oxygen
production (k) were calculated by plotting change in absorption of DPBF at 410 nm






Relative singlet oxygen quantum yields were determined using the equation
below with Rose Bengal as the reference. k: rates of singlet oxygen production, ΦΔ:




Flow cytometry. U87 cells (300,000 cells/well) were incubated in glucose-free KRB
buffer including or not compound 15 (100 µM) for 1 h. Cells were illuminated or
not with visible light (10 mW). Following incubation in fresh DMEM for 16 h, cells
were detached, resuspended in KRB buffer, and analyzed by flow cytometry using
Annexin V-Pacific BlueTM (4 µg mL−1, λexc/em: 405/450 nm). Flow cytometry data
were analyzed using FlowJo.
Live-cell fluorescence confocal microscopy. U87 cells were plated in glass
chamber slides (NuncTM Lab-TekTM II) in supplemented DMEM medium (20,000
cells/well). After 4 h, cells were incubated with or without compounds 15 or 2-NBDG
(100 µM) in KRB buffer for 1 h and illuminated or not with visible light (10mW, 37 J
cm−2). Prior to imaging experiments, cells were incubated with Annexin V-Pacific
BlueTM (4 µgmL−1) and imaged in a Leica SP8 confocal microscope (λexc/em: 405/
450 nm for Annexin V, λexc/em: 488/530 nm for 2-NBDG, and λexc/em: 488/590 nm for
compound 15). All images were processed and analyzed using ImageJ.
Glioblastoma spheroids. U87-nlsCrimson cells were plated in Corning ultra-low
attachment 96-well plates (500 cells/well) in supplemented DMEM medium and
incubated for 72 h at 37 °C in a humidified atmosphere with 5% CO2. Spheroids
were incubated with or without compound 15 (100 µM) for 1 h and illuminated or
not with visible light (10 mW, 37 J cm−2) before being washed and imaged on a
widefield fluorescence EVOS microscope (Olympus) (λexc/em: 610/645 nm). The
spheroids diameter was measured after 48 h incubation at 37 °C and size decrease
measurements were normalized to untreated spheroids. All images were processed
and analyzed using ImageJ.
Human brain cell cocultures. HCN-2 cells (15,000 cells/well) were plated in 6-well
glass chamber slides (NuncTM Lab-TekTM II) and incubated with CellMask Green
for 30 min. U87-nlsCrimson cells (10,000 cells/well) were then added to the wells
and co-incubated for 4 h at 37 °C in a humidified atmosphere with 5% CO2.
Cocultures in glucose-free KRB buffer were incubated with or without compound
15 for 1 h and illuminated or not with visible light, followed by imaging in Leica
SP8 confocal microscope (λexc/em: 488/520 nm for CellMask Green and λexc/em:
561/645 nm for E2Crimson). All images were processed and analyzed using ImageJ.
In vivo zebrafish experiments. Experiments were carried out in accordance with
Committee-approved ethical procedures. 48 hpf larvae were anesthetized using
MS222 and mounted in 3% methylcellulose. U87-nlsCrimson (~50 cells/fish) were
grafted into the edge of the yolk sac of larvae using a glass needle. Successfully-
grafted larvae were selected under a dissecting fluorescence microscope. Larvae
were injected with compound 15 (6 pg/embryo) and illuminated or not with visible
light (10 mW, 37 J cm−2). The tumor mass in grafted larvae was imaged at 24 h
posttreatment by embedding in low-melting agarose and acquiring fluorescence
images of U87-nlsCrimson cells in a Leica SP8 confocal microscope (λexc/em: 561/
645 nm). Images were processed and analyzed using Imaris. Zebrafish were han-
dled and maintained in the BVS aquatic facility at the University of Edinburgh
according to standard protocols60. Animal experimentation was approved by the
ethical review committee of the University of Edinburgh and the Home Office in
accordance with the Scientific Procedure Act 1986.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1b, 2c, 3c, 4b, c, 5e, 6b, d and Supplementary Figs. 2 and
4 are provided as a Source data file. Additional data that support findings of this study
are available from the corresponding authors upon reasonable request. Source data are
provided with this paper.
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